Limin Xia, Wenjie Huang, Dean Tian, Lin Zhang, Xingshun Qi, Zhangqian Chen, Xin Shang, Yongzhan Nie, Kaichun Wu – 5 September 2013 – Forkhead box Q1 (FoxQ1) is a master regulator of tumor metastasis. However, the molecular mechanism of FoxQ1 in regulating hepatocellular carcinoma (HCC) metastasis remains unknown. Here we report a novel function for FoxQ1 in modifying the tumor microenvironment to promote HCC metastasis. FoxQ1 expression was an independent and significant risk factor for the recurrence and survival in two independent cohorts totaling 1,002 HCC patients.

Florian Douam, Viet Loan Dao Thi, Guillemette Maurin, Judith Fresquet, Dimitri Mompelat, Mirjam B. Zeisel, Thomas F. Baumert, François‐Loïc Cosset, Dimitri Lavillette – 4 September 2013 – Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are important mediators for productive cell entry. However, knowledge about their structure, intra‐ or intermolecular dialogs, and conformational changes is scarce, limiting the design of therapeutic strategies targeting E1E2.

Matthew J. Armstrong, Leon A. Adams, Ali Canbay, Wing‐Kin Syn – 3 September 2013 – Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is strongly associated with the metabolic syndrome. In the last decade, it has become apparent that the clinical burden of NAFLD is not restricted to liver‐related morbidity or mortality, and the majority of deaths in NAFLD patients are related to cardiovascular disease (CVD) and cancer.

Véronique Loustaud‐Ratti, Paul Carrier, Chanlina Vong, Marie Essig – 3 September 2013

Marjon Kerkhof, Pieter Honkoop – 3 September 2013

Matthew J. Armstrong, Leon A. Adams, Ali Canbay, Wing‐Kin Syn – 3 September 2013 – Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is strongly associated with the metabolic syndrome. In the last decade, it has become apparent that the clinical burden of NAFLD is not restricted to liver‐related morbidity or mortality, and the majority of deaths in NAFLD patients are related to cardiovascular disease (CVD) and cancer.

Chiun Hsu, Hsiao‐Hui Tsou, Shyh‐Jer Lin, Ming‐Chung Wang, Ming Yao, Wen‐Li Hwang, Woei‐Yau Kao, Chang‐Fang Chiu, Sheng‐Fung Lin, Johnson Lin, Cheng‐Shyong Chang, Hwei‐Fang Tien, Tsang‐Wu Liu, Pei‐Jer Chen, Ann‐Lii Cheng, on behalf of the Taiwan Cooperative Oncology Group – 3 September 2013 – Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti‐HBc] positive) can occur, but the true incidence and severity remain unclear.

Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A. Price, Hubert E. Blum, Christoph Neumann‐Haefelin, Robert Thimme – 3 September 2013 – Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with a poor prognosis and limited therapeutic options. To aid the development of novel immunological interventions, we studied the breadth, frequency, and tumor‐infiltration of naturally occurring CD8+ T‐cell responses targeting several tumor‐associated antigens (TAA).

Pooja Jha, Thierry Claudel, Anna Baghdasaryan, Michaela Mueller, Emina Halilbasic, Suman K. Das, Achim Lass, Robert Zimmermann, Rudolf Zechner, Gerald Hoefler, Michael Trauner – 3 September 2013 – Hepatic inflammation is a key feature of progressive liver disease. Alterations of fatty acid (FA) metabolism and signaling may play an important role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH).

Benjamin Goeppert, Carolin Konermann, Christopher Roman Schmidt, Olga Bogatyrova, Lea Geiselhart, Christina Ernst, Lei Gu, Natalia Becker, Manuela Zucknick, Arianeb Mehrabi, Mohammadreza Hafezi, Frederick Klauschen, Albrecht Stenzinger, Arne Warth, Kai Breuhahn, Marcus Renner, Wilko Weichert, Peter Schirmacher, Christoph Plass, Dieter Weichenhan – 3 September 2013 – The molecular mechanisms underlying the genesis of cholangiocarcinomas (CCs) are poorly understood.